Expert Interview
A Second Opinion: Looking at Cardiff Oncology's Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC)
Ticker(s): CRDFInstitution: Advanced Care Oncology And Hematology Associates
- Medical Oncologist & Partner at ACOHA (private practice in New Jersey); fellowship trained at New York Presbyterian-Columbia University Medical Center.
- Manages ~400 patients with solid tumors and 25 patients with gastroesophageal junction cancer.
- Lectures widely on Gastrointestinal and Genitourinary malignancies.
Roughly how many patients with colorectal cancer do you manage?
Added By: ben_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for onvansertib?
Added By: ben_adminHow do you interpret the P2 data of onvansertib?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
